CoChat

Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Open access
Yulug, Burak, Altay, Ozlem, Li, Xiangyu, Hanoglu, Lutfu, Cankaya, Seyda, Lam, Simon, Velioglu, Halil Aziz, Yang, Hong, Coskun, Ebru, Idil, Ezgi, Nogaylar, Rahim, Ozsimsek, Ahmet, Bayram, Cemil, Bolat, Ismail, Oner, Sena, Tozlu, Ozlem Ozdemir, Arslan, Mehmet Enes, Hacimuftuoglu, Ahmet, Yildirim, Serkan, Arif, Muhammad, Shoaie, Saeed, Zhang, Cheng, Nielsen, Jens, Turkez, Hasan, Borén, Jan, Uhlén, Mathias, Mardinoglu, Adil · 2023 · Translational Neurodegeneration

Published version of a preprint

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Abstract

Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress. Methods: Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L -serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl- L -cysteine (12.75%), and 3.73 g L -carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients. Results: We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 ( P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline ( P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment. Conclusion: Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis. Trial registration ClinicalTrials.gov NCT04044131 Registered 17 July 2019, https://clinicaltrials.gov/ct2/show/NCT04044131

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-023-00336-2

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CMA improves ADAS-Cog scores and clinical parameters. a Study design for testing the effects of CMA in AD patients. b Differences in ADAS-Cog scores in the CMA and placebo groups on days 0, 28 and 84. The ADAS-Cog scores were further analysed by stratifying the patients into high- (score > 20) and low-ADAS-Cog score (≤ 20) groups. The ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FoldChange [FC] = − 0.33, 26% improvement, P = 0.0000003) and on day 84 vs day 0 (Log2FC = − 0.37, 29% improvement, P = 0.00001) in the CMA group. A slight but significant decrease was found in the placebo group on day 28 vs day 0 (Log2FC = − 0.16, 12% improvement, P = 0.009) and on day 84 vs day 0 (Log2FC = −0.19, 14% improvement, P = 0.001). In addition, the ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FC = − 0.31, 24% improvement, P = 0.002) and on day 84 vs day 0 (Log2FC = − 0.38, 30% improvement, P = 0.003) in the high-score CMA group, while no significance difference was seen in the high-score placebo group. c We selected 10 patients from the severe (ADAS-COG score > 20) CMA group with matched ADAS-COG values to the placebo group (P-value: 0.693) and presented the ADAS-Cog scores. We recalculated the differences in ADAS-COG scores and found significant improvement in the CMA group whereas there was no significant difference in the placebo group. d Heatmaps showing log2FC-based alterations of the clinical variables before vs after treatment in both CMA and placebo groups. Asterisks indicate statistical significance based on Student’s t-test (P < 0.05)
Fig. 1 CMA improves ADAS-Cog scores and clinical parameters. a Study design for testing the effects of CMA in AD patients. b Differences in ADAS-Cog scores in the CMA and placebo groups on days 0, 28 and 84. The ADAS-Cog scores were further analysed by stratifying the patients into high- (score > 20) and low-ADAS-Cog score (≤ 20) groups. The ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FoldChange [FC] = − 0.33, 26% improvement, P = 0.0000003) and on day 84 vs day 0 (Log2FC = − 0.37, 29% improvement, P = 0.00001) in the CMA group. A slight but significant decrease was found in the placebo group on day 28 vs day 0 (Log2FC = − 0.16, 12% improvement, P = 0.009) and on day 84 vs day 0 (Log2FC = −0.19, 14% improvement, P = 0.001). In addition, the ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FC = − 0.31, 24% improvement, P = 0.002) and on day 84 vs day 0 (Log2FC = − 0.38, 30% improvement, P = 0.003) in the high-score CMA group, while no significance difference was seen in the high-score placebo group. c We selected 10 patients from the severe (ADAS-COG score > 20) CMA group with matched ADAS-COG values to the placebo group (P-value: 0.693) and presented the ADAS-Cog scores. We recalculated the differences in ADAS-COG scores and found significant improvement in the CMA group whereas there was no significant difference in the placebo group. d Heatmaps showing log2FC-based alterations of the clinical variables before vs after treatment in both CMA and placebo groups. Asterisks indicate statistical significance based on Student’s t-test (P < 0.05)CC BY · PubMed Central
Fig. 2 Identification of clinical variables informative for response to CMA administration. a Distribution of ADAS-Cog scores over visits for patients with ALT level ≤ 16 IU/l (upper panel) and ALT > 16 IU/l (lower panel) at visit 1. b Between-visit changes of ADAS-Cog score in AD patients stratified by other various clinical variables. Only those clinical variable groupings resulted in a more significant change of ADAS-Cog in the CMA group compared to the placebo group is shown (P < 0.05). The colour scale indicates log2 fold change of ADAS-Cog score between visits. Statistical significance between visits was determined by a paired t-test across individuals who attended both visits. Asterisks indicate a statistical significance of P < 0.05
Fig. 2 Identification of clinical variables informative for response to CMA administration. a Distribution of ADAS-Cog scores over visits for patients with ALT level ≤ 16 IU/l (upper panel) and ALT > 16 IU/l (lower panel) at visit 1. b Between-visit changes of ADAS-Cog score in AD patients stratified by other various clinical variables. Only those clinical variable groupings resulted in a more significant change of ADAS-Cog in the CMA group compared to the placebo group is shown (P < 0.05). The colour scale indicates log2 fold change of ADAS-Cog score between visits. Statistical significance between visits was determined by a paired t-test across individuals who attended both visits. Asterisks indicate a statistical significance of P < 0.05CC BY · PubMed Central
Fig. 3 CMA alters plasma metabolite levels. a Differences in the plasma levels of individual CMA, including serine, carnitine, cysteine and nicotinamide on days 0 and 84. b–d Plasma levels of amino acids, lipids and other metabolites that were significantly different between day 84 and day 0 in the CMA and placebo groups. Adjusted P < 0.05. Heatmap shows log2FC values of metabolites between day 84 and day 0. Asterisks indicate statistical significance based on paired Student’s t-test. Adjusted P < 0.05. Log2FC: log2(fold change)
Fig. 3 CMA alters plasma metabolite levels. a Differences in the plasma levels of individual CMA, including serine, carnitine, cysteine and nicotinamide on days 0 and 84. b–d Plasma levels of amino acids, lipids and other metabolites that were significantly different between day 84 and day 0 in the CMA and placebo groups. Adjusted P < 0.05. Heatmap shows log2FC values of metabolites between day 84 and day 0. Asterisks indicate statistical significance based on paired Student’s t-test. Adjusted P < 0.05. Log2FC: log2(fold change)CC BY · PubMed Central
Fig. 4 Correlation of CMA with plasma metabolites and altered plasma protein levels. a Associations between the plasma levels of individual CMA and the 10 most significantly correlated plasma metabolites. Asterisks indicate statistical significance (Adjusted P < 0.05) based on Spearman correlation analysis. Cor.Coeff: Correlation coefficient. b Heatmap showing log2FC-based significantly different proteins on day 84 vs day 0 in the CMA and placebo groups. Asterisks indicate statistical significance based on paired Student’s t-test (P < 0.01). c Integrated multi-omics data based on network analysis represent the neighbours of the CMA, including serine, carnitine, nicotinamide and cysteine, and ADAS-Cog scores. Only analytes that were significantly altered in CMA on day 84 vs day 0 are highlighted
Fig. 4 Correlation of CMA with plasma metabolites and altered plasma protein levels. a Associations between the plasma levels of individual CMA and the 10 most significantly correlated plasma metabolites. Asterisks indicate statistical significance (Adjusted P < 0.05) based on Spearman correlation analysis. Cor.Coeff: Correlation coefficient. b Heatmap showing log2FC-based significantly different proteins on day 84 vs day 0 in the CMA and placebo groups. Asterisks indicate statistical significance based on paired Student’s t-test (P < 0.01). c Integrated multi-omics data based on network analysis represent the neighbours of the CMA, including serine, carnitine, nicotinamide and cysteine, and ADAS-Cog scores. Only analytes that were significantly altered in CMA on day 84 vs day 0 are highlightedCC BY · PubMed Central
Fig. 5 Structural magnetic resonance imaging analysis. a Increased cortical thickness (red-yellow) in the study group (P < 0.05) in the inferior parietal, lateral occipital and middle frontal and paracentral cortical regions based on the illustration of FreeSurfer's Qdec application. b Segmentation maps of the hippocampal subfields displayed on the sagittal (top), axial (middle), and coronal (bottom) planes. c Hippocampal subfield measurements showing increased volumes in the study group (P < 0.05) in the left mean hippocampal (upper left) and left hippocampal molecular layer (lower left) based on the FreeSurfer's Qdec application. Other sub-anatomic hippocampal regions iii) including left CA1 body (upper right) and iv) left whole hippocampal body (lower right) were not significant but near to a statistically significant level (P > 0.05)
Fig. 5 Structural magnetic resonance imaging analysis. a Increased cortical thickness (red-yellow) in the study group (P < 0.05) in the inferior parietal, lateral occipital and middle frontal and paracentral cortical regions based on the illustration of FreeSurfer's Qdec application. b Segmentation maps of the hippocampal subfields displayed on the sagittal (top), axial (middle), and coronal (bottom) planes. c Hippocampal subfield measurements showing increased volumes in the study group (P < 0.05) in the left mean hippocampal (upper left) and left hippocampal molecular layer (lower left) based on the FreeSurfer's Qdec application. Other sub-anatomic hippocampal regions iii) including left CA1 body (upper right) and iv) left whole hippocampal body (lower right) were not significant but near to a statistically significant level (P > 0.05)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 150 references

Research works printed but not linked: 3

  1. Turkez H, Altay O, Yildirim S, Li X, Yang H, Bayram C, et al. Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases. Life Sci. 2023;InPress. · DOI
  2. Hou Y, Wei Y, Lautrup S, Yang B, Wang Y, Cordonnier S, et al. NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS-STING. Proc Natl Acad Sci U S A. 2021;118(37): e2011226118. · DOI · Paper page
  3. Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876–85. · DOI · Paper page

Cited by

See all 86

Metadata

Authors
Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., Nogaylar, R., Ozsimsek, A., Bayram, C., Bolat, I., Oner, S., Tozlu, O. O., Arslan, M. E., Hacimuftuoglu, A., Yildirim, S., Arif, M., Shoaie, S., Zhang, C., Nielsen, J., Turkez, H., Borén, J., Uhlén, M., & Mardinoglu, A.
Affiliations
  • King's College London (GB)
  • Science for Life Laboratory (SE)
  • Alanya Alaaddin Keykubat Üniversitesi (TR)
  • Atatürk University (TR)
  • Erzurum Technical University (TR)
  • Chalmers University of Technology (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Uhlén, Mathias
Venue
Translational Neurodegeneration
Published
2023-01-26
Volume
12
Issue
1
Pages
4-4
ISSN
2047-9158 (ISSN-L)
OpenAlex
W4318195490
Cited by
79
References
150
Citations by year
2026: 14 · 2025: 23 · 2024: 24 · 2023: 15
FWCI
13.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Alanya Alaaddin Keykubat University Institutional Repository (submittedVersion, cc-by-nc-nd)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Chalmers Research (Chalmers University of Technology) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Knut och Alice Wallenbergs Stiftelse (72110)
  • Royal Institute of Technology
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
Alzheimer's disease, cognitive function, L-serine, nicotinamide riboside, N-acetylcysteine, mitochondrial fatty acid oxidation, oxidative stress, NAD+ metabolism, glutathione metabolism, plasma metabolome, plasma proteome, hippocampal volume, cortical thickness
MeSH terms
Alzheimer Disease, Animals, Cognition, Double-Blind Method, Humans, Treatment Outcome, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. https://app.cochat.ai/papers/10.1186/s40035-023-00336-2
The paper
Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., Nogaylar, R., Ozsimsek, A., Bayram, C., Bolat, I., Oner, S., Tozlu, O. O., Arslan, M. E., Hacimuftuoglu, A., Yildirim, S., . . . Mardinoglu, A. (2023). Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Translational Neurodegeneration. https://doi.org/10.1186/s40035-023-00336-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.